Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
- Baird analyst Brian Skorney initiated coverage on Alumis Inc. (NASDAQ:ALMS) with an Outperform rating and announced a price target of $25. Alumis shares closed at $11.23 on Wednesday. See how other analysts view this stock.
- Jones Trading analyst Soumit Roy initiated coverage on Enliven Therapeutics, Inc. (NASDAQ:ELVN) with a Buy rating and announced a price target of $36. Enliven Therapeutics shares closed at $28.39 on Wednesday. See how other analysts view this stock.
- HC Wainwright & Co. analyst Swayampakula Ramakanth initiated coverage on Intensity Therapeutics, Inc. (NASDAQ:INTS) with a Buy rating and announced a price target of $5. Intensity Therapeutics shares closed at $3.05 on Wednesday. See how other analysts view this stock.
- Oppenheimer analyst Jay Olson initiated coverage on Terns Pharmaceuticals, Inc. (NASDAQ:TERN) with an Outperform rating and announced a price target of $17. Terns Pharma shares closed at $6.89 on Wednesday. See how other analysts view this stock.
- Macquarie initiated coverage on Braze, Inc. (NASDAQ:BRZE) with a Neutral rating and announced a price target of $30. Braze shares closed at $32.00 on Wednesday. See how other analysts view this stock.
Considering buying ALMS stock? Here's what analysts think:
Read More:
- Wall Street's Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 8% Dividend Yields
